StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.06−0.44 (-12.57%)

Close on Nov 18, 2026Market cap $62.83KP/E –Yield –

Addex Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -CHF 2.81M. The highest annual figure on record is -CHF 1.42M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-CHF 2.81M–
FY2024Dec 31, 2024-CHF 2.76M–
FY2023Dec 31, 2023-CHF 2.24M–
FY2022Dec 31, 2022-CHF 10.54M–
FY2021Dec 31, 2021-CHF 15.51M–
FY2020Dec 31, 2020-CHF 12.24M–
FY2019Dec 31, 2019-CHF 14.60M–
FY2018Dec 31, 2018-CHF 1.42M–
FY2017Dec 31, 2017-CHF 3.24M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-CHF 645.35K–
Q2 FY2025Jun 30, 2025-CHF 732.90K–
Q2 FY2024Jun 30, 2024-CHF 899.32K–
Q2 FY2023Jun 30, 2023-CHF 2.55M–
Q2 FY2022Jun 30, 2022-CHF 7.09M–
Q2 FY2021Jun 30, 2021-CHF 4.51M–

More Addex Therapeutics figures

See a number that looks wrong?